CGEN - Earnings call transcript Q3 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. [Operator Instructions] An audio webcast of this call is available in the Investors section of Compugen's website, www.cgen.com.

As a reminder, today's call is being recorded. I would now like to introduce Yvonne Naughton, Head of Investor Relations and Corporate Communications. ahead. go please Yvonne,

Yvonne Naughton

and today. all Joni, on joining the call thank you, for you us Thank

triple from for David Medicine, me Medical by of General President Officer; an Joining Dr. Compugen Dr. Officer. and Anat Chief Director are us and and Dr. Translational combination our Hospital, investigator who Assistant to School Oncology today. Chief Massachusetts Cohen-Dayag, the Research, for study, We're Dr. Medical Program, Oladapo also Executive Scientific be cancer Mahler, Yeku, Harvard also Boston, Officer; Michelle Silberman, is delighted on discuss Financial join which IO the ovarian Gynecologic Chief Q&A. Officer, we'll Chief prepared will joined remarks of Ofira, Professor Alan

for that, results to you our we the XX-F. in uncertainties, expectations statements potential you projections call, we remind company regarding timelines over performance statements and statements plans, on discovery only I'll as begin, position. company wish these We and the our we and progress for risks, and cash future including that obligation projections with forward-looking Anat. refer to recent assumptions, call future. on company's These their beliefs, the such or but you well like update turn studies, And company actual caution platform, to statements the the current the The report to business most statements undertakes would details no programs financial accounting-related annual differ and the and filings outcome, may Form forward-looking known SEC this events risks results, more unknown materially. efforts achievements reflect as or of regarding are to our to make may and and company's anticipated subject that development during and matters company's outlook, Before and

Anat Cohen-Dayag

advanced presented We're fresh our us encouraging around conference SITC our When back we an and data in studies, activity cancer of that XX on were data platinum-resistant to to supporting call. We consistency looking data our we COMXXX, ovarian the quarter everyone, confirm ovarian platinum-resistant from our pretreated heavily our be able not highly ovarian in our blockade where overall We're to for rate, patients, in cancer. this our between on hypothesis. development response than welcome COMXXX-driven range discussions Houston, in third of only today Pembrolizumab Yvonne, XXXX patients. with demonstrating at cohort you, the data be and high. previously X more additional plans. thank of joining COMXXX, I'm presented part discussion Dr. Texas, and cancer by the to you, on and delighted triple encouraged Thank lots of platinum-resistant the Yeko considered the call recognize had patients and safety may XX% we the

data, typically partial What important agent However, in population consistent this immunotherapy. patient X of was in than treated it COMXXX responses months with this drug XX% studies XX including of response for months. totality reported in the historically one COMXXX This XX of more patient consider rate is and is exemplified where control to our responding the poor a as in study data lasting a a to presented disease tolerability out prior was and combination. durability clinical outcomes evaluating stands in the have of other the we good a single patients, of that also not a with with we

would of indication COMXXX-driven system that effect. reinforces disease data COMXXX, PVRIG where a this we relevance pharmacodynamic a a of a activation offers this. earlier expect of but and there translational further explain supports the immune unmet addition, in setting An rationale indicates ovarian of clinical I data has opportunity. where to need development further most in supporting cancer such is unique an in now the robust where mechanism mechanism In fits its overall supporting path This significant action COMXXX will of be a the effective. action the disease advanced and biology

less Firstly, there received profile durable face treatment. an patients and in fit is the a setting in COMXXX's who may have has maintenance for would care maintenance safe for ovarian prior this have consequently, no need to in options have durability therapy treatment maintenance potential platinum-sensitive be tolerability and where and advantage this therapy and may for options women gap cancer competition. relapsed differentiated maintenance additional treatment and highly

therefore, these disease progression and than change the and are pretreated providing time harness less COMXXX its immunotherapy mechanism more to the heavily of opportunity Secondly, patients immune potentially trajectory action to compromised, are for the unique patients increase disease. advanced of to less the

tertiary of platinum-sensitive a these and clinical has the biological stem strong Advancing cancer structures therefore, maintenance COMXXX T treated lymphoid and In rationale and previously ovarian less competitive landscape. memory mechanism to potential chemotherapy cells. into this its of the also has leveraging action been patients unique consideration by it addition, in induce to COMXXX on to the setting takes of has and cells the chemotherapy with platinum-based sensitize tumors shown

platinum-sensitive to ovarian regimens patients have candidates X planned chemotherapy least at be not relapsed in received are of receive is cancer trial maintenance standard-of-care an platform lines to trial who prior platinum-based treatment. adaptive and Our

be primary assessing sub-study stepwise, will be will double-blinded survival, opportunity. monotherapy in endpoint progression-free as and therapy for opening approach for expected be Such a randomized COMXXX and initially randomized allows X be XX development with months. placebo enrolling the additional benchmark a will the placebo. to X:X COMXXX to a who design providing patients a substudies maintenance regulatory single-agent median Our starting where platform approximately or future, is commercial The

further TG our triplet permit evaluation backbone treatment COMXXX testing inhibitors, combination the like DNA with in checkpoint would substudies agents hypothesis. Additional of a as combination anti-PD-X

bevacizumab, would full PARP, substudies options the with partners Additional exploring or potentially others extract combination of to COMXXX. also ADCs, permit potential like additional

As we strategies. exploratory potential employing platform biomarker plan design, enrichment of part to assessment the various continue of

experts the We for This and from all strong a feedback XXXX path. are the data analysis who been to ovarian regulatory this to randomized interim development options boxes the with the cancer supportive of by registration may encouraged It has path open clinical HX XXXX. various development path ticks arm for a enable and combinations, we from very important of agree and QX door believe for the on biological plan COMXXX. partnering in are engagement the to expect authorities of We trial COMXXX initiate have forward. in the selected therapy have maintenance rationale,

to study suffice backbone. makes with mono into clinic, future also COMXXX runway, further interim of a and additional advancement sense it investment projected arms, XXXX continued gradual together focus pipeline. COMXXX is COMXXX perspective, and a reach while Importantly, allowing inflow support anticipated cash in earlier financial as in expected of to key no from a catalysts, analysis investment potential including on combo the assuming Cash in we our

we and where third achieving this And which of safety our cancer track relate FDA the Before were received handing progress of see I a is to from study gastric are we this payment over data the World I had financials, cytokine to and on our the lung Conference and is biology derived $XX Lung at initiate quarter. treat we the Gilead. and in Fc-reduced to excited both IND cancer, Cancer million bispecific, Rilvegostomig, from in the promising with clearance, briefly David to their profile Starting manageable COMXXX. TIGIT harness from showing to quarter. we component Phase milestone partner, run approach AstraZeneca's quarter, partnered with efficacy to the presentation to In PD-X differentiated COMXXX, through Gilead our TIGIT ESMO want for great a other the to

cancer TROPION-LungXX, and cancer In trials assess and recently ADC Pembro cell adjuvant Phase or will are cell non-squamous tiered for strategy future that, With Rilvegostomig David over Rilvegostomig AstraZeneca I fifth ARTEMIDE-X, monotherapy with source lung high-risk as sales. milestone This Rilvegostomig, hand fourth non-small on will and revenue royalties non-squamous mid-single-digit broad and PD-LX. payments combination to frontline in in with AstraZeneca chemo by expressing announced to eligible significant which chemo compared potential combination future update. both for as we in which lung as assess represents with non-small therapy a addition, early-stage Rilvegostomig resected for in Dato-DXd III patients of its financial will development with Compugen the

David Silberman

saying I our will afternoon I'm that of cash be now and you, start by Thank as extremely would and balance. results to like to summarize good to pleased here everyone. our part team. Anat, financial with Compugen start today morning I and

December of cash compared million had XX, As approximately of with investments approximately September equivalents and $XXX.X cash, $XX.X as XX, we in XXXX. XXXX, million

in expenses with company cash Revenues IND of revenues Our period clearance third decrease mainly of to for Gilead to R&D of revenues lower were the to XXXX. achieved fund comparable in a from Gilead XXXX. with $X.X COMXXX million, our expenses due reflect QX for for upfront portion the quarter R&D our with payment revenues, the The the is in no agreement the classification has of cost third plans XXXX. million debt. with expected $XX of received is the for runway into mainly were $XX.X no quarter in quarter COMXXX CMC. reduced approximately from license from plan. of the current XXXX XXXX milestone were the third The to COMXXX $X.X and XXXX July. of line Expenses activities for related payment of million million compared The recognition coupled

third million of of the XXXX. million Our quarter quarter G&A the to XXXX $X.X in expenses third $X.X for were comparable

diluted and XXXX, $X.X million hand net loss Yeku. per or For and the or $X.X the diluted share quarter on With $X.XX share details million into per $X.XX net to of a Michelle third compared of over more XXXX. in of recorded basic of chat basic to results will Dr. the data profit with we and to third I the fireside moderate that, go quarter a

Michelle Mahler

for at David. provide and combination by future triple to unmet patients. need using to COMXXX, be I'm Yeku of COMXXX an medical with ovarian joined the overview the Pembrolizumab encouraging delighted date Thank last opportunity of I'm the Friday, experience Yeku happy with you, significant Dr. to Dr. very and the which to data, discuss his presented and cancer combined SITC in

all tolerable, computational of cancer TIGIT anti-PVRIG identified Using and first capabilities, ovarian PVRIG durable as high-priority study ovarian platinum-resistant of options. blockade, triplet ovarian we antibodies initiation indication PD-X think justifying our know significant we associated blockade without could effects. women benefit cancer with frightening is toxic with and safe, treatment is drug of the alternative, for medical diagnosis the potentially unmet who of need There doubt, cancer for its side our efficacious the treatment the I that, and cancer from evaluating patients. in

significant and Given to of of platinum-resistant another excited patients in included SITC the Fc-reduced at clinical patients, Pembrolizumab or ovarian the were in unmet The anti-PD-X The previous cancer cancer study ongoing they platinum-resistant COMXXX our was in of a XX of patients Yeku of platinum-resistant of triplet Dr. combination in a reported assess small number anti-TIGIT combination when treated shrinking triplet of COMXXX, and a our with cancer durable presented stabilization validation the checkpoint COMXXX XX% findings. ovarian patients similar benefit and in investigators had therapies of treatment advanced patients other goal this to with and need had data these disease. the COMXXX, the an cohort and no demonstrate alternative a most had prior a could prior X tumors we whether prior study patients. similar prior the known that pretreated set prior with Pembrolizumab. where patients investigational limited had are pretreated the The prior histology heavily resistant. Notably, of they suggesting to and be study entering of option. to immune with median thus treatment were the had were agent, characteristics PARP data either options bevacizumab inhibitor. treatment of or population ADC heavily XX% presented patients treatment of XX% had Patients ovarian

at as with prior exposure patients still responses previously had patients confirmed it treatment most in notable previously response on response. advanced had and stable reported one a safe than in that patient PARP as PD-X inhibitors to them the assessment responsive of profile. this rate XX%. a patients lesion well blockers tolerability remain was investigational not to complete Also This The who similar responses what heavily in advanced objective TIGIT have patients X active target with X treatment, control as other of immunotherapy to whom presented. were agents study XX%, of their X COMXXX with were as is been with of and the a of rates cutoff, partial important remember on of and including reduction data patients confirms days that including in good last XXX study. ADC than response, XX.X% overall and disease durable than However, more on these is the rate we disease of excites more with with a reported patients setting. for and XX% complete data disease, with the patients the All had the the study presented response tumor us are the in with and responses pretreated or treatment X less blockade and for combination past historically particularly of PD-X

tolerated. resulting a chemo treatment-emergent were events There of no safety X less. course profile combination platinum-sensitive as to or triple grade change disease. well the combination discontinuation X The an Treatment-related Grade ovarian well which a is the and In lending for less confirms opportunity data grade and X%. system totality stacks up well-known as immune is good to chemotherapy setting profile adverse in responses or This COMXXX compromised, the is that relevant for one the contrasts associated monotherapy were in in X development encephalopathy with and our compared durable of safety terms profile SMART that immunotherapy treatment active majority COMXXX serious justify the and tolerability, events. of was and, There X ADCs. discontinuation. to to adverse further immune-related cancer, the tolerability The was and showed treatment-emergent observed safety particularly favorable importantly, of was toxicity a

profile extend staff, the I safety to to favorable greater regimen. maintenance thanks investigators, as in our the like study our setting even and drugs this addition, differentiation becomes point is In Yeku plans. Welcome, earlier of an patients a and would their Yeku. sincere pleasure the short and my welcome to our chat in for to families participating development Dr. trials. a discuss clinical presented just future fireside It data for Dr. of our

Oladapo Yeku

me. you having Thank for so much

Michelle Mahler

ovarian becoming with describe with I landscape ovarian Would for first current patients please will cancer question. treatment cancer? to the in from start you briefly resistant moving my platinum-sensitive

Oladapo Yeku

Thank you, Michelle.

with the only be are bevacizumab that patients platinum-resistant the have to function. to of commonly this a is where important late. think the an I which their been several again, used X recently, for preserve progress than to from to subject drug patients past, their we in retreated our the Thank X ovarian this disease, that And a months that with the most are with become it prime we've disease. disease, relapse. types antibody key to to prior unfortunately, means preventing used. chemotherapy first a of restricted platinum-based unfortunately, of to remember of a best time, towards more relapse or date, to, progressive this in are chemotherapy. platinum-based platinum-resistant PARP more inhibitors, And to platinum-sensitive suppressed And over it's area most advanced going establish disease, lot disease relentless mirvetuximab as combination, very at quality and despite There referred state, less cancer maintenance example. The as which efforts, it's patients indicates that life, of patients interval, to least of these inevitable for strive the you. has preserve being as such usually And nature call therapies, doublet explored These with of now which is months, these platinum-sensitive that is inevitably our was because patients platinum-free progression that most triplet interval, has a but to typically that thing bevacizumab. an a these conjugates, efforts decreases time patients indication minimum

Michelle Mahler

and of bothersome a you? more patients comment you the to Can your of the out challenges restrictive as bit some well as little late toxicities point that about

Oladapo Yeku

therapies of we reasons course, one of so explore side of continued bevacizumab. to the that effects Of is other had the because maintenance

in be another of swept combination migraines, such is What arthalgias, that therapy typically are myalgia They sleeps. be under mentioned typically that's XX concerns. disease. effects, ones. that common to with bevacizumab, carboplatin is tends a I our have more patients heart no is tends have because in used the platinum-sensitive they lot are triplet population disease, And as effects patient side -- and rug more more that the our Now serious which, with side to those fistulas, and above again, chemotherapy strokes, the serious perforations, of

therapies, several we patients to other that inhibitors maintenance BRCA repair when PARP it drug, homologous promise promise. including reason, this exposed with explored showed mutations deficiencies PARP lot of and showed of types initially this For a inhibitors. were

the these into found platinum-sensitive this So especially several vast indications And inhibitors that unfortunately, as not FDA and ones data of harbor But withdrawal could mature detrimental. drugs the we over that patients, these for PARP actually PARP platinum-resistant moved setting. majority to we to inhibitors. do continue the of these mutations, for led the be time,

For for our because down the of patients is who These day-to-day side and our have their effects. inhibitors, concern AML their cytopenias. syndrome are later myelodysplastic use line, candidates and significant increased disease the drugs this in cause for rates PARP there fatigue,

they approved, therapies upfront to many who of down PARP and can XX complete our on. these move be fact, In the count setting inhibitors and when where bevacizumab patients receive it's with FDA in really the months

Michelle Mahler

sound not very does Wow, good patients. those for

some platinum-resistant ovarian in of that Pembrolizumab are with data? treated? there any COMXXX cancer, you anecdotes What you've week? the takeaways What patients some COMXXX, you share study triplet that at which our from excites you in with about And SITC gear switch background are the with us me could specifically place. let of your presented then from key So and last patients with

Oladapo Yeku

Of course.

we many patients whom on treated the chemotherapy. of for this were patients single-agent So that study

taxol which mentioned, if setting, patients these disease, what spurred weekly folate toxic like vast effect, low response have on with participating for part the they receptor are expression but outside platinum-resistant conjugates of low this enthusiasm only at is the chemotherapy in these I or with single-agent response So of particular which rates mirvetuximab And chemotherapy chemotherapy. looking is the around and have in of the antibody patients drug were requisite durability majority study. this rate XX%

key benefit. the And study me point always thing relapsed XX% power has in long-term this excited leaves rates, with XX% a of to say, was a X have response potential ovarian to desired, the many high about that Even therapies cancer. durability let's drugs the weekly being that for be about in this average I toxicity XX% Now for X been key to our taxol, ignoring our weekly the the mentioned, the response response months. taxol, rate, of rate, lot

forward that with is months. Let's and however, mirvetuximab, fast the median still folate survival. look in receptor, patients PFS approved currently shows But which for X is high at improvement and overall

patients when even concern I have high that response have is drugs that So is an issue. these a great always durability rates,

study, me come So our to X that this the particular COMXXX other excited our one things this trials, leave about with had I anecdotes, for patients always mind. that effect. And this the experience durable X really was prospect based with study. I'll prior you on knew of

experience on the bit going. this patients typically until study, from that because them warned at disease had had to a least a immunotherapy get always that that to been of to symptomatic one counseled immunotherapy, had had little wait their few I our months takes time paradigm date, first relief they I The with

started pain pleasant lady my had relief opioids abdominal on in pain when this weeks. within of study, so who she the had relief, fact, matter was, a particular And significant

to before take better opioids life, better. day-to-day she setting, a received quality getting the or less what of around really, of which and second already even in infusion is second was get a I focus more, So She's cycle on her turn, life. treatment, her had able really in platinum-resistant

to on outcome knew wait. have She somebody this was study a positive going we was right to the So away. that didn't who have

driving The one patients forgo a with again they function, watched physician setting, of their they're is patients, life. treat diagnosed by many cases, their where setting. people care second down and in withdrawing They're bit though they better, worn therapy, the ocular in maintenance or they're in We they is that setting, quality I get leave their And who disease, have that time. And disease the this drive that them reach maintenance sort of example. they to, the they anecdote most of a you want taking We little from be night, continue and even finish they they're lose with degradation weaker, platinum-sensitive back. little things we've I'll to as depleted. afraid somebody of mirvetuximab degrade the otherwise these platinum-resistant taking don't or they toxicity watching when sobering activities the that because ability a more over of quitting at we comes retiring jobs, start platinum-resistant of treat my loved. stop therapy process bit newly time patients into a for

quite to conversation, quit yet. One of job I nice "Don't the is a this -- your study things able was I we had have about said, who same patient the that

and get see remained triplet and haven't can a take you how don't really, for think week COMXXX are my the work. and toxicity process. effects. laptop. prior cautiously and day, I'm hair." The just those my there do." family, even And I'm treatment. time We I several I've continue back development. to with know the say, have she keep patients name, you drug study side of a throughout stories, walked home, you message nauseous. long I my to this I you for any medications lost that very, gave up, I of also go get lot not on so, I sent one-on-one a you at both but think show very back seen next for I was stories, waiting it's or But work really my know preliminary us this others, of Every infusion. in both that area relief, lot not "I'm their on a really I'm of And of my in patients those to optimistic studies. who let's by hope. another those

Michelle Mahler

data to patients glad understand patient SITC? did including that call was that the really Can particular you Can the patient hear agents at presented bit these of comment exposure characteristics, patient's transition population the I'm well. on I the investigational this help histology prior the on little relevant conjugates and well in about the a the little Wow. the responses antibody-drug from bit as to and just a as background this population? and baseline to those observed more

Oladapo Yeku

Of course.

survival. bevacizumab with of have these Again, overall patients are trial have mirvetuximab, I these setting or for these the all questions, they've exhausted whom setting meant to I that in upfront in bevacizumab, patients reasonable of you patients treatments. shown exposed most have [indiscernible], we've prior progressed remind all been been were exposed of PARP platinum-sensitive And of its to inhibitors. excluding had also started, in mentioned, on think, either that in have to one inhibitors this them your And who to even when because exposed case, -- the or have the PARP also we inhibitors. PARP most that seen As been been toxicities. that Many in of

world, still drug. not only clinic, other cancers. or few carcinomas many patients any epithelial of or The represented representative options and the like are patients coming high-grade key of a BRCA had somatic for who then platinum-resistant becoming left So the high-grade are real is whom patients histologies germline harbored investigational in here people off as we treat are well. the And And those which of these were or them in we mutations. chemotherapy patients

that have know rescued again, So have very generally with on and PARP early very we wouldn't disease. aggressive been inhibitors patients are these

study in real Now this captured also life. patients

not creatinine around XX,XXX, hemoglobin XX,XXX, the So including levels the the criteria this to who to lines sort been These patients highlight. ill we platinum-resistant important early very of of And multiple who X, some patients if real-life study, we meet exposed patients, that on I your look in almost with alternatives, of that of responses -- see around were the class to are think patients the fact had of that platinum-sensitive eligibility these at the is your you have of able platelets did population not setting. few we are of very in treatment.

Michelle Mahler

Yeku, use I just pick cancer? the choose are journey? the with wanted the about more terms you you to that be could future of had especially else maybe with thinking about a about about agents wanted we in plans with of reasons course something or the some bit the patient's in talk a the where again would here would think emerging ask exciting, little landscape, what to ovarian you see COMXXX And such choice, if of combination before what and COMXXX versus on I a of antibody -- -- just conjugates you to drug

Oladapo Yeku

They've And schedules chemo we've down chemo, you to lives. antibody a to drug we actually different wanted get conjugates, in prevent given remind more lower that what because you little you so cumulative comes daily that a tried their reasonably not the with became toxicity we by we're them. toxic And with can lower could the therapy and giving even still at a past, think effects with Michelle. that call really dose cancer, the I gentler the our on but some the sort people problems, chemo found was ovarian drugs, you of and domain just temporary maintenance toxicity. they're solved though I'll have dose it for bit stretch problems tolerability, out recurrence. it of same to of our urgent in people on grateful gave side all schedule, or pick

their a For themselves. my worried in They're they're every They are you they many day-to-day real. before, patients, take to of They I night they degradation to some is care anymore. as about cough, concerned. of concern. pneumonitis. at about vision. don't no is have way time And your real That toxicity a mentioned patients, Ocular drive very live It's very live alone, concerned life.

of a maintenance. lot has So It ADCs, see work that daily any a hepatotoxicity, blood or we where continue counts. a very of effects it's to with tend best infusion. definition where treatment decrement a really weekly or newer even in the or ocular lot seeing not don't tolerable to pneumonitis fits a And schedule, people of has we're toxicity the can side

now And that itself, every by and patients impact daily transfusions. already these function. these So people's need are will then and will side get anemic effects

yet side but continue more allow the platinum-sensitive So to was or elucidated done life, maintenance both for to combinations a setting the like that combined already for a it's potential upfront in we best for, me, clinical control long recurrent of drug for disease seen that of having COMXXX live many bevacizumab mind, in have looking have very the rate I what effects the don't the with we've with that. options. benefit setting and or the could think my we some But rate that their to where urgently been we've the and people side effects very, has have therapies time,

Michelle Mahler

a as next you touched follow-on because relapsed maintenance. we So a COMXXX question for you platinum-sensitive earlier, moving heard to just evaluating respect forward are with on setting study my in

increasing is potential would of study. this platinum-resistant? them and in you as change to population, setting in And you you believe So various this by the impact and the do PFS a what hopefully excite elements the about patient for target that to disease? terms from terms that understand becoming course of on also our to the wanted What thoughts of this the your population little bit I there are delaying be touch with

Oladapo Yeku

Of course, Michelle.

things X So about with, X I my the are we these in think patient, host the this about people know. terms, immunologic And domains. the people we or thinking in big the there are in is mind. is live way One big

worsening they We round lines that than ability each the mount early immunotherapy, go know you the sort go of round fledgling benefits data mentioned, in reason, chemotherapy. recurrence the for As of you Many I frailer, down the this people's the immunotherapy myelotoxic down change. versus less when for them X, illnesses. get and you treatment. studies, shown responses platinum-resistant, is same therapy, associates translational data immune diagnosis, out of them are through marrows there of to to cytotoxic greater they to after and after have weaker, affects them round setting. our or platinum-sensitive lives to break break they response that fewer recurrence, are by rates the as common further platinum-sensitive of universally, response go. exposed round lines than of through after universally, cytotoxic They system get all number greater When early of their And affects and bone as the prior a preference X, by of chemo,

that big first about So something immune system, something that compartment exposure thing. marrow, That's changes chemo. each the about the we know bone there's lymphoid the to about subsequent with something the

exposure X each chemo. worse. or We iteration after each this gets cycles With itself. know organizing even we organizing from the disease stroma, surgeries the cancer of is reduction to chemotherapy, thing find where fibrosis [indiscernible] second The

moving more stalemate, curing tumor consider where in are oncology, you if disease. best is person background, toxic either their homes, but with a problem that will their people to tumor mechanisms each where less both will, they the And cancer know a host will of get the in each to that them we treatment And in chemotherapy anybody might hypertension, is working, we're at each not exposure, the recurrence, This some somebody is right? or function, the the has also vitality. engaged that exposure, this. the in family, next yet the patient terms can little achieve deployed. of you something they're person really converts the can somebody subsequent And you can the for hopeful we trial because has to in to the tell line, leading doing, care that like that so cancer them we the we with also keep cetera, option you with patient sort their chemotherapy, now have of the disease diabetes evolves disease able them a function. chronic The So each employ, sort give through keep them, [ solid can observe the into maintain tumor immunologic evolution mutations, keep giving somebody drugs, taking ] when who in and people to alter opposite biology knows And an with of not worse a best, does more itself setting diverge that et stave to get of We maintenance them thing it's earlier means off outcomes. fashion advantage of capture where are stabilized worst. then

who and see So of heavily we hope, really other things less that That of the culminate see and that's fatigue patients this, eventually these are I is less pretreated. sort in all how Michelle. cachexia,

Michelle Mahler

sensitive on this in study. grateful our that the provided, our have patients really future for different Yeku into insight. we to to have results maintenance for you. as as you really, us thank forward well work participated the us and next continuing your the as that go summarize, place for to context understand you and much, really to platinum-resistant respect want Thank Dr. landscape that you context with us understand the cancer I helping our used study the well very drugs and to ovarian appreciate To helping and so look to to with and support evolving are I Also being also put as to

for will questions. operator I over call turn Now the the to

Operator

question Instructions] first The Stephen is [Operator Willey from Stifel. of

Stephen Willey

what the is? prior platinum me you that requiring of for Michelle, lines I of the Phase mentioned could would have you X, but just number in number be think that remind may proposed terms been you

Michelle Mahler

Sure.

patients the therapy had So patients inhibitor of PARP. a who be a with PARP be we not chemotherapy will platinum-containing with with prior and for a maintenance targeting and regimens additional candidate or either X lines or maintenance bevacizumab bev had have have have must

there where the line be get second our conventional any additional in standard-of-care for basically patients, to exceptions but predominantly the addresses therapy questions? maintenance So wish have and may Do this or with third-line study. eligible you patients may maintenance be not

Operator

follow-up of is Stephen next The -- Willey Stifel. from there a question is question from

Stephen Willey

Yes.

Sorry about that.

think I dropped queue. out the of the operator

what's line prior to you're but if of going So platinum-sensitive Yeku have and pursuing are third setting? is proportion be line, and/or and sure the line just can your still within still maintenance bev exhausted patients answer Dr. the third PARP I'm this, given of who understanding on the not and get to

Michelle Mahler

Otherwise, to Yeku to take happy Dr. if and going answer. just I'm I'm like would line So on the to that. is check

Oladapo Yeku

can an I opinion. Okay. offer

platinum-resistant. a So do the after population small first of to is biology majority different a is horrible We chemotherapy completely vast patients patients very progress. clinic. diagnosis, see their will that recurrence get That is have they of in and

will is Most rare. that then time, recurrence become that And patients over Fortunately, platinum-resistant. platinum-sensitive first. relatively a exhausted, after therapy have is

patients, majority So also most X phase. cancer, the the the of Stage in incidentally through and common will, of on ones X diagnosis diagnosis, go Stage their stages point vast some at which especially journey are platinum-sensitive the ovarian with a for

has with it have least I for That's because or of concerning inhibitor up least mentioned amount patients that before, the their indications brought maintenance. of the think had PARP actually of first-line risk amount we PARP where the danger. inhibitors most we've will Now

patients X have might many who have received would there patients fusions Stage it and have with or those already most on would So plural especially had ascites diagnosis, disease bevacizumab.

bevacizumab of is majority have platinum-sensitive setting, been a would PARP through for because either inhibitor for bevacizumab. waypoint, who the either first toxicity, may platinum-sensitive and declined reserve would of a they of a PARP few many or There platinum-resistant patients they or mutations exposed germline those the of didn't first-line So we to were But our passing of majority any the declined have and/or received that line HRD vast therapy, inhibitor positive. always at concerns bevacizumab who which choosing them cut the have in to it PARP if one, patients because setting. be vast the will second be

Stephen Willey

build just the you may single-agent And development know Michelle be and on path an here. maybe I combo. Okay. mentioned I there for know potentially opportunity again. then Anat to pursuing you're

COMXXX on to additional activity really single-agent the get setting of is what is So once perhaps then that data? therapies have layer a an of understanding to this kind this you opportunity for you combination-based in of and better look

Anat Cohen-Dayag

it And try that's for to start a have go centric contribution mono open a try combination. is us free in well. and door with population for the are effect into that, we feel it that getting Yes, to as to to may this patient for us, but really for irrespective opens a that to But single path for great monotherapy, opportunity add. the Michelle, where design of COMXXX agent nothing

the tick a So potentially and all clinical for from us it regulatory really perspective. boxes perspective

Operator

is The next Graybosch. Daina question from

Daina Graybosch

Two questions for me.

and I'll them The a take one first, at time.

Dr. PD-X bevacizumab. seem me, can some Michelle, we with remember were with trials The to first antagonist? PD-LX is, and you remind from what Yeku learned or I trials relevant there similar that

been we in done? this about learn those trials So And did what's already setting? what

Oladapo Yeku

offer I response. a can

It's is that. generally different in and So for your with we've even checkpoints. in done range the bad. I combinations. multiple are a bevacizumab common done other discuss combinations can done combinations chemotherapy We've lines. nonstarter. Monotherapy overall wouldn't be XX% rates XX% typically And we've very the with is around combination. that responses immune response different multiple that We've with some learned class although in to drugs patients, low, PD-X lessons durable, combinations

of before, as these heavily in, deep we X, of which lines will better some learned not But have platinum-sensitive we've and saw testing these and/or to Many a is those we And responses, is them long-lasting we X also the would that of developed and not where that number but saw However, found started. bit tended lines setting, patients are platinum-resistant durable long still, what responses. of did mentioned respond really started patients in matter. that's patients, When What well. little we of durability. here, we the responses. I pretreated it up X more X or we drugs very typically platinum-resistant, moved have therapy,

benefit. course earlier a you likely So we made also, more have are connection in use the the disease, less that lesson earlier the their the again, in is it to sick second of the you patient,

of more with combinations, exploration for is rates. maybe upfront, inhibitor to those We've bevacizumab. we response you a little mixed. the it still less combine PARP our but a we PARP months, get which toxicity example, with same, have with the cost survival When combined it, different couple upfront the around with boosted of of by led terms been progression-free effects In pay excitement The combinations. bit inhibitors,

long-lasting fact, but plus now chemotherapy In many and benefits, of chemo. And effects bevacizumab combination oral combination right those oral a only the of patients at of of of bevacizumab plus our is side have is cytoxan, a pembrolizumab. type compendium-listed which cost again, the

Some this taxol. weekly patients to refer

the responses especially summary, have to experience checkpoints, and in use will ipilimumab decreased patients learned these have our we durable many these some like partners. One of with better. immunotherapy, range with both earlier but at X recent We've nivolumab, learned X long-standing we've that that that rates the the said, is was the of combination the of drugs. combination So we and cost overall. it response rates for have We've response the those combine can response learned boost that you response also most to example approaching of survival other progression-free but you then we associated with was to And rates of were final allow with months. study again, up rates, will saw I the of like toxicities with combinations, to again, chemo, if XX%, we want things, improved in

for to in toxicities So perspective, inhibition again, with one cetera, colitis, really if thinking it. nobody months, et that's patient's be on CTLA-X you study just wants of a the yourself X the about which put scan,

to go been skepticism I around question. that. So there's a again, that next answered your bit where hope little of with

Daina Graybosch

this maintenance maybe been line same The does. the one third No. sort second in any to And Were lacking drug Yes, of has exact really, of studies space setting? in those development. terms platinum-sensitive after setting follow-up. it platinum maintenance specific of really

think cisplatin The platinum-resistant trials. I a study is of looked that maintenance can of Pembrolizumab the closest lot setting. a done haven't in We gem and at

like quite sort means also not So gem the as Pembrolizumab setting. continue a then chemo, was the the that maintenance. the and the and you thing, would agent of platinum the cisplatin was the in would of almost you use but they idea use same platinum-resistant this the But

was the typical response response, what progression-free of but months higher X So rate, platinum-resistant we again, in see survival around the for is which they that setting. got a durability

ride. gem looked felt wasn't and combination. worth it really of we the at cis PD-LX newly diagnosed whole haven't they in looked with We've setting, upfront at toxicity the But sustenance. So disease that

mentioned not you And or trials were [indiscernible] I somebody those did. think futile.

Anat Cohen-Dayag

Eran, say a angle, why PD-X and employed in there? work why next at maybe we just believe you maybe it should to we're before should want setting looking believe the from it question, this while we be COMXXX

Eran Ophir

Yes, sure.

have be going and have eventually T in very, though way Mostly, patients. into cells, environment, patients failed settings, didn't drive also actually by tested ovarian of the because will but that's with really the cells as patients negative almost cells unique of which modulated why above And in T in in occur respond And So the -- what that these PD-X had negative therapy. aren't. published action, most shown T were to And cell least. very to PD-X. PD-LX than PVRIG at or monotherapy. all of seen. of checkpoint, driving them you it PD-LX is quite T in monotherapy sufficient not do stem-like Dr. memory a Yeku monotherapy. mentioned, its very have blockade it's patients recently, potential. mechanism blockade cancer in other we And responded if Yes, has X a but to biology this the has many and also is And different this have and these PVRIG, actually we we yes, the COMXXX patients indications and tumor are checkpoints activity we for the potential some proliferative above immunologically which had CPS test XX us. PD-X to PVRIG patients, PD-LX strong this even difficult We

different blockade and tumor and the the that was the to to after in settings that do PVRIG change especially TSCM induce think TS chemotherapy also earlier disease biology blockade the has to very and a potential effect. has PVRIG course, that we shown So synthesize that platinum-based

Operator

Tony is Renshaw. question next Butler of The & from Rodman

Tony Butler

on one. it speed GOG it of would that. and to in I'm if months. XX the setting in enrollment durability fact, But is Michelle, events, be? an is that PFS two that theory, XX actually as And the the or into, et Is progression-free it most And patients, is the rather median that to months? necessary in comments importantly, most still going to Yeku, platinum-sensitive survival if, agent months, make adverse Dr. enrolling is But PFS in question you're to be That's question relevant. Is you're respectful what's as I well that of the which you're suggest cetera? understand moving X ideal XXX around case I for is, need would guess, engage such in rapid? what X the clinically

Michelle Mahler

take Okay. I that. will

know actually don't the we So size. effect

at want and However, three a control a the usually, least improvement it's bit of rule of a over thumb, we month to arm. see

aiming So or months. by placebo X we arm are the observation arm for the beating

the are as heavily GOG. goes, far As GOG engaged who opinion involved we in leaders the key have

still and study, are of conversations small we to they However, several those in support this development, investigators. with later-stage a is but tend relatively

Oladapo Yeku

relevancy clinical the to add might discussion. I if Michelle,

means therapy, decreases. of after So I mentioned patients interval their progress that these platinum-sensitive that to that platinum-resistant. before each from is And what line

later, X then back, get So something. come months the comes maybe cancer they first time plus back it might platinum the

when finish transition. make therapy, it comes months it they back, after back time that and second The that comes X that's they

if mark, them means you've that kept For many that patients, get is what month X that mark, platinum-sensitive. them X X, to month we

tolerable our to That's biology at and people So with when are or eligible and less with PFS and know, what for least they agent of nothing starts based -- and that all a tick than something platinum-resistant. really to window the do when X decreasing ignoring changes, we older it's clinically that we alter data, they're it now tips -- on that's the day-to-day, down. clock live different It's a almost bucket, with else. when the debate of reinduction when platinum-sensitive means what's patients maintenance in platinum what's keeping by patients that

as making the them anything X maintaining becomes X platinum-sensitive or I approach again think really So you meaningful. months, above platinum X, months sensitivity

fact, you platinum-sensitive, are, better patients the we data longer, In patients are with of have do that X platinum-sensitive a more than but XX platinum-sensitive a with live months interval months. Both platinum-sensitive than interval the better. greater

X So is that months what clinically. shoot we for X,

Operator

The from is Securities. next Truist question of Asthika Goonewardene

Asthika Goonewardene

upfront for apologize it's earnings I us. because a joined late heavy call day I the

looking this any cutoffs Phase Could TIGIT provide any why biology what bit there's little rudimentary you'd in great. So if any of the and to of been be that And also of could implement? sort II Phase or well there do sense would not this question, you And does study? address this feedback maybe make also to a agency as to II, on looking then addressed in be for the apologies already. sort into be II -- if you'd this any about for analysis maybe development has talk biomarker a you here And going study? understanding Phase if [indiscernible]

Anat Cohen-Dayag

the to then relate relate questions, Eran let I'll first the and two FDA part. So Michelle to

Eran Ophir

Yes.

study. in did XX So a chance IO the still before, to yes, in we the this fast did have as after we biomarkers PVRLX we extremely point And patients, like biomarker of thanks, the complex. Ashik. case as which progressed never the platinum-resistant of know ADCs of actually fraction have it's have in followed potential had don't initial have enough not in mentioned target for we this the itself. others so the challenging. a and in our of is benefit, now because while all the that biomarker, to antibody It's more probably some that signal an is IO a Obviously, a with. very important XX%, impact roughly setting. begin to And clinical enrich And the up And patients, it's

biomarker So the enrich And would have enough one prospective the for is point, study. of to PVRLX. data to by for enrichment-based at the this indeed patients be not approach these looking an

the should patient did, discussed we to an the more setting we and attributes immune going we now sufficient which in -- before. a what are have other earlier all system we So

actually, study are we the are we biomarker and again itself. we have continue for -- follow the But we by design So this another the and going also up trend, did not by indication. because response to added needing design to

some going we PVRLX potential. also to So the up biomarker other follow on are to in and study continue coming

going future it. have to biomarker for still not we're a opportunity exists for coming have But and again, biomarker the substantiate studies. the the this So to to one,

biology. TIGIT For

you shown we So first II amount currently I But a is have of all, Phase randomized I blockade. TIGIT -- TIGIT active sufficient active. we X and think of mentioned know, think what before you for have that when cells amount have as -- sufficient studies PD-X into blockade is microenvironment. T -- different when

in ovarian could shown it cells can the TIGIT block landscape, cancer to COMXX be that you use that So in will be T you have then we PVRIG tumor, when yes, relevant. and definitely drive

shown that's PD-X have showing amount will a or sufficient PVRIG study. plus we've And, of definitely, treating After previously. relevant. PD-X plus doing with TIGIT one the most blockade to also activity, be why cells COMXX PD-X after the then you TIGIT platform as of reasonable blockade, do T If could next be step blockade, we're

So relevant, in could could this and done be approach. be TIGIT definitely a stepwise

Michelle Mahler

Yes.

question. take going to I'm So the

being spoken And of So terms have within have FDA with of with elements blinded. then would the next at got conversation well haven't the that good the we the It's what it a the time, clinical to as We've in randomized well would steps. in data, very that's a positive the as event FDA. framework we be in be updated guidance. yet this trial point designed to robust

Operator

participation. for This concludes you Thank the your conference Q&A call. session and investor Compugen's

go may and You ahead disconnect.

Compugen (CGEN) 12 Nov 242024 Q3 Earnings call transcript